Brief Eclectic Psychotherapy for PTSD - a Randomized Controlled Trial
Launched by UNIVERSITY OF ZURICH · May 23, 2006
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clear memory of an "index" traumatic event (sufficient for constructing a scene to be used in exposure) that occurred no less than six months prior to entering the trial (Montgomery and Bech 2000)
- • PTSD according to the DSM-IV, related to the index traumatic event, as measured with the CAPS: frequency ≥ 1 and intensity ≥ 2 for a symptom to be counted plus a minimum level of overall severity ≥ 50
- • Not receiving other psychotherapy for PTSD during the 16 weeks of active treatment; psychotherapy for other problems, brief check-ins with an existing therapist, and attendance at self-help groups will be allowed
- • If on psychoactive medication: on a stable medication regimen for a minimum of two months prior to entering the trial
- • Aged between 18 and 70 years
- • Sufficient proficiency in the German language to participate in BEP
- • Consent to be randomized into the trial
- Exclusion Criteria:
- • Current psychotic, bipolar, substance-related, or severe personality disorder
- • Current severe depressive disorder
- • Severe cognitive impairment or a history of organic mental disorder
- • Evidence of PTSD or depression immediately prior to the index trauma
- • Ongoing threat of traumatic exposure
- • Prominent current suicidal or homicidal ideation
- • Asylum seeking status
About University Of Zurich
The University of Zurich, a leading institution in research and education, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust framework for conducting high-quality research, the university collaborates with multidisciplinary teams of experts to explore cutting-edge therapeutic approaches and interventions. Its commitment to ethical standards and patient safety ensures that all clinical trials are conducted with the utmost integrity, aiming to contribute valuable insights to the medical community and enhance health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zurich, , Switzerland
Patients applied
Trial Officials
Ulrich Schnyder, MD
Principal Investigator
University of Zurich
Lutz Wittmann, MA
Principal Investigator
University of Zurich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials